Sprout Marketing

Sprout Pharmaceuticals is a specialty biopharmaceutical company dedicated to the development and commercialization of therapies for women's sexual health. The company is best known for its flagship product, Addyi (flibanserin), which was the first FDA-approved treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Sprout gained significant industry prominence following its $1 billion acquisition by Valeant Pharmaceuticals in 2015, shortly after Addyi's approval, and its subsequent return to its original shareholders in 2017. The company continues to focus on expanding access to Addyi and advocating for the medical recognition of female sexual dysfunction as a biological condition requiring pharmacological intervention.